Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V.

J Am Soc Nephrol. 2019 Oct 1. pii: ASN.2019040331. doi: 10.1681/ASN.2019040331. [Epub ahead of print]

PMID:
31575699
2.

Adherence profiles in kidney transplant patients: Causes and consequences.

Villeneuve C, Rousseau A, Rerolle JP, Couzi L, Kamar N, Essig M, Etienne I, Westeel PF, Büchler M, Esposito L, Thierry A, Marquet P, Monchaud C.

Patient Educ Couns. 2019 Aug 7. pii: S0738-3991(19)30318-0. doi: 10.1016/j.pec.2019.08.002. [Epub ahead of print]

PMID:
31447197
3.

Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens.

Delville M, Lamarthée B, Pagie S, See SB, Rabant M, Burger C, Gatault P, Giral M, Thaunat O, Arzouk N, Hertig A, Hazzan M, Matignon M, Mariat C, Caillard S, Kamar N, Sayegh J, Westeel PF, Garrouste C, Ladrière M, Vuiblet V, Rivalan J, Merville P, Bertrand D, Le Moine A, Van Huyen JPD, Cesbron A, Cagnard N, Alibeu O, Satchell SC, Legendre C, Zorn E, Taupin JL, Charreau B, Anglicheau D.

J Am Soc Nephrol. 2019 Apr;30(4):692-709. doi: 10.1681/ASN.2018080868. Epub 2019 Mar 8.

PMID:
30850439
4.

Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.

Bailly E, Anglicheau D, Blancho G, Gatault P, Vuiblet V, Chatelet V, Morelon E, Malvezzi P, Parissiadis A, Tourret J, Guidicelli G, Sayegh J, Mousson C, Grimbert P, Top I, Le Quintrec M, Purgus R, Westeel PF, Proust B, Chabot V, Lebranchu Y, Dehaut F, Büchler M.

Transplantation. 2018 Apr;102(4):688-698. doi: 10.1097/TP.0000000000002002.

PMID:
29135832
5.

Pronase treatment improves flow cytometry crossmatching results.

Apithy MJ, Desoutter J, Gicquel A, Guiheneuf E, Westeel PF, Lesage A, Piot V, Choukroun G, Guillaume N.

HLA. 2017 Sep;90(3):157-164. doi: 10.1111/tan.13073. Epub 2017 Jun 28.

PMID:
28660746
6.

The association between killer-cell immunoglobulin-like receptor (KIR) and KIR ligand genotypes and the likelihood of BK virus replication after kidney transplantation.

Brochot E, Desoutter J, Presne C, De Araujo I, Flahaut G, Castelain S, Westeel PF, Choukroun G, Guillaume N.

Transpl Int. 2016 Nov;29(11):1168-1175. doi: 10.1111/tri.12820. Epub 2016 Sep 12.

7.

Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes.

Liabeuf S, Desjardins L, Massy ZA, Brazier F, Westeel PF, Mazouz H, Titeca-Beauport D, Diouf M, Glorieux G, Vanholder R, Jaureguy M, Choukroun G.

Circ J. 2016;80(3):722-30. doi: 10.1253/circj.CJ-15-0949. Epub 2016 Feb 4.

8.

One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.

Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, Ducloux D, Chatelet V, Moulin B, Freguin C, Hazzan M, Lang P, Legendre C, Merville P, Mourad G, Mousson C, Pouteil-Noble C, Purgus R, Rerolle JP, Sayegh J, Westeel PF, Zaoui P, Boivin H, Le Gouge A, Lebranchu Y.

Transplantation. 2016 Feb;100(2):391-9. doi: 10.1097/TP.0000000000000958.

PMID:
26555944
9.

Access to preemptive registration on the waiting list for renal transplantation: a hierarchical modeling approach.

Riffaut N, Lobbedez T, Hazzan M, Bertrand D, Westeel PF, Launoy G, Danneville I, Bouvier N, Hurault de Ligny B.

Transpl Int. 2015 Sep;28(9):1066-73. doi: 10.1111/tri.12592. Epub 2015 Apr 28.

10.

Treating diabetes with islet transplantation: lessons from the past decade in Lille.

Vantyghem MC, Defrance F, Quintin D, Leroy C, Raverdi V, Prévost G, Caiazzo R, Kerr-Conte J, Glowacki F, Hazzan M, Noel C, Pattou F, Diamenord AS, Bresson R, Bourdelle-Hego MF, Cazaubiel M, Cordonnier M, Delefosse D, Dorey F, Fayard A, Fermon C, Fontaine P, Gillot C, Haye S, Le Guillou AC, Karrouz W, Lemaire C, Lepeut M, Leroy R, Mycinski B, Parent E, Siame C, Sterkers A, Torres F, Verier-Mine O, Verlet E; G4 working groups, Desailloud R, Dürrbach A, Godin M, Lalau JD, Lukas-Croisier C, Thervet E, Toupance O, Reznik Y, Westeel PF.

Diabetes Metab. 2014 Apr;40(2):108-19. doi: 10.1016/j.diabet.2013.10.003. Epub 2014 Feb 6. Review.

PMID:
24507950
11.

Correlation between Luminex donor-specific crossmatches and levels of donor-specific antibodies in pretransplantation screening.

Guillaume N, Mazouz H, Piot V, Presne C, Westeel PF.

Tissue Antigens. 2013 Jul;82(1):16-20. doi: 10.1111/tan.12128. Epub 2013 Apr 29.

PMID:
23621167
12.

Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.

Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, Morelon E, Moal V, Janbon B, Alamartine E, Pouteil Noble C, Morel D, Kamar N, Buchler M, Mamzer MF, Peraldi MN, Hiesse C, Renoult E, Toupance O, Rerolle JP, Delmas S, Lang P, Lebranchu Y, Heng AE, Rebibou JM, Mousson C, Glotz D, Rivalan J, Thierry A, Etienne I, Moal MC, Albano L, Subra JF, Ouali N, Westeel PF, Delahousse M, Genin R, Hurault de Ligny B, Moulin B.

J Clin Oncol. 2013 Apr 1;31(10):1302-9. doi: 10.1200/JCO.2012.43.2344. Epub 2013 Feb 19.

PMID:
23423742
13.

Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine.

Joannidès R, Monteil C, de Ligny BH, Westeel PF, Iacob M, Thervet E, Barbier S, Bellien J, Lebranchu Y, Seguin SG, Thuillez C, Godin M, Etienne I.

Am J Transplant. 2011 Nov;11(11):2414-22. doi: 10.1111/j.1600-6143.2011.03697.x. Epub 2011 Sep 19.

14.

The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study).

Abou-Ayache R, Büchler M, Le Pogamp P, Westeel PF, Le Meur Y, Etienne I, Hurault de Ligny B, Toupance O, Caillard S, Sinnasse-Raymond G, Touchard G.

Transplant Proc. 2011 Sep;43(7):2630-5. doi: 10.1016/j.transproceed.2011.05.050.

PMID:
21911136
15.

Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study.

Lebranchu Y, Thierry A, Thervet E, Büchler M, Etienne I, Westeel PF, Hurault de Ligny B, Moulin B, Rérolle JP, Frouget T, Girardot-Seguin S, Toupance O.

Am J Transplant. 2011 Aug;11(8):1665-75. doi: 10.1111/j.1600-6143.2011.03637.x.

16.

[Results of nephrectomy for native kidney tumors in renal transplanted patients].

Tillou X, Viart L, Demailly M, Hakami F, Westeel PF, Saint F, Petit J.

Prog Urol. 2011 May;21(5):322-6. doi: 10.1016/j.purol.2010.09.028. Epub 2011 Mar 29. French.

PMID:
21514534
17.

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.

Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E; RAD A2420 Study Group.

Transpl Int. 2010 Nov;23(11):1084-93. doi: 10.1111/j.1432-2277.2010.01094.x. Epub 2010 Aug 19. Erratum in: Transpl Int. 2012 Jan;25(1):138.

18.

A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.

Etienne I, Toupance O, Bénichou J, Thierry A, Al Najjar A, Hurault de Ligny B, Le Meur Y, Westeel PF, Marquet P, François A, Hellot MF, Godin M.

Nephrol Dial Transplant. 2010 Sep;25(9):3096-106. doi: 10.1093/ndt/gfq135. Epub 2010 Mar 17.

PMID:
20299336
19.

De novo renal carcinoma in renal transplant recipients: effect of early treatment.

Tillou X, Demailly M, Hakami F, Westeel PF, Saint F, Petit J.

Transplant Proc. 2009 Oct;41(8):3314-6. doi: 10.1016/j.transproceed.2009.08.036.

PMID:
19857739
20.

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J; RAD A2420 Study Group.

Transplantation. 2009 Jul 15;88(1):69-76. doi: 10.1097/TP.0b013e3181aa7d87.

PMID:
19584683
21.

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B.

Am J Transplant. 2009 May;9(5):1115-23. doi: 10.1111/j.1600-6143.2009.02615.x.

22.

CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.

Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G.

Nephrol Dial Transplant. 2008 Jun;23(6):2024-32. doi: 10.1093/ndt/gfm873. Epub 2008 Jan 16.

PMID:
18199693
23.

Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.

Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P.

Am J Transplant. 2007 Nov;7(11):2496-503. Epub 2007 Oct 1.

24.

[Proportion of surgical workload related to chronic renal failure in an urology and transplantation operating room].

Tillou X, Moriniere P, Hakami F, Demailly M, Fourmarier M, Westeel PF, Saint F, Petit J.

Prog Urol. 2007 Jun;17(4):832-5. French.

PMID:
17633996
25.

Insulin maintains plasma antioxidant capacity at an early phase of kidney transplantation.

Monge M, Ledemé N, Mazouz H, Lalau JD, Moubarak M, Presne C, Fournier A, Mazière JC, Choukroun G, Westeel PF.

Nephrol Dial Transplant. 2007 Jul;22(7):1979-85. Epub 2007 Apr 20.

PMID:
17449497
26.

Drug Insight: renal indications of calcimimetics.

Shahapuni I, Monge M, Oprisiu R, Mazouz H, Westeel PF, Morinière P, Massy Z, Choukroun G, Fournier A.

Nat Clin Pract Nephrol. 2006 Jun;2(6):316-25. Review.

PMID:
16932453
27.

Severe Pneumocystis pneumonia in a renal transplant recipient after long term mycophenolate mofetil treatment.

Totet A, Westeel PF, Nevez G.

Rev Inst Med Trop Sao Paulo. 2005 Sep-Oct;47(5):303-4; author reply 305. Epub 2005 Nov 16. No abstract available.

28.

Renal artery aneurysm secondary to Candida albicans in four kidney allograft recipients.

Laouad I, Buchler M, Noel C, Sadek T, Maazouz H, Westeel PF, Lebranchu Y.

Transplant Proc. 2005 Jul-Aug;37(6):2834-6.

PMID:
16182825
29.

Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment.

Büchler M, Lebranchu Y, Bénéton M, Le Meur Y, Heng AE, Westeel PF, le Guellec C, Libert F, Hary L, Marquet P, Paintaud G.

Clin Pharmacol Ther. 2005 Jul;78(1):34-42.

PMID:
16003290
30.

Multiple clustered dermatofibromas on a superficial venous thrombosis in a kidney-transplanted patient.

Viseux V, Chaby G, Agbalika F, Luong MS, Chatelain D, Westeel PF, Denoeux JP, Lok C.

Dermatology. 2004;209(2):156-7. No abstract available.

PMID:
15316173
31.

[Cutaneous T-cell lymphoma following renal transplantation].

Defossez-Tribout C, Carmi E, Lok C, Westeel PF, Chatelain D, Denoeux JP.

Ann Dermatol Venereol. 2003 Jan;130(1 Pt 1):47-9. French.

PMID:
12605158
32.

Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine.

Ghez D, Westeel PF, Henry I, Pruna A, Fournier A, Lassoued K.

Am J Kidney Dis. 2002 Aug;40(2):E6.

PMID:
12148127
33.

[MELAS syndrome (mitochondrial encephalopathy with lactic acidosis and stroke-like episodes].

Carmi E, Defossez C, Morin G, Fraitag S, Lok C, Westeel PF, Canaple S, Denoeux JP.

Ann Dermatol Venereol. 2001 Oct;128(10 Pt 1):1031-5. French.

PMID:
11907964
34.

[Renal osteodystrophy (1): invasive and non-invasive diagnosis of its pathologic varieties].

Oprisiu R, Hottelart C, Ghitsu S, Said S, Westeel PF, Morinière P, el Esper N, Pruna A, Fournier A.

Nephrologie. 2000;21(5):229-37. Review. French.

PMID:
11068772
35.

[Renal and hypertensive complications of extracorporeal lithotripsy].

Bataille P, Pruna A, Cardon G, Bouzernidj M, el Esper N, Ghazali A, Westeel PF, Achard JM, Fournier A.

Presse Med. 2000 Jan 15;29(1):34-8. Review. French.

PMID:
10682057
36.

Captopril prevention project--what shall we do about captopril and the risk of stroke?

Fournier A, Pruna A, Esper NE, Makdassi R, Oprisiu R, Westeel PF, Mazouz H, Achard JM.

Nephrol Dial Transplant. 2000 Jan;15(1):2-5. Review. No abstract available.

PMID:
10607758
37.

Renal and hypertensive complications of extracorporeal shock wave lithotripsy: who is at risk?

Bataille P, Cardon G, Bouzernidj M, El Esper N, Pruna A, Ghazali A, Westeel PF, Achard JM, Fournier A.

Urol Int. 1999;62(4):195-200. Review.

PMID:
10567881
38.

Risk factors of renal failure progression two years prior to dialysis.

Mazouz H, Kacso I, Ghazali A, El Esper N, Moriniere P, Makdassi R, Hardy P, Westeel PF, Achard JM, Pruna A, Fournier A.

Clin Nephrol. 1999 Jun;51(6):355-66.

PMID:
10404696
39.

[Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis].

Kacso I, Gherman M, Mazouz H, Ghazali A, el Esper N, Morinière P, Makdassi R, Hardy P, Westeel PF, Achard JM, Pruna A, Fournier A.

Nephrologie. 1999;20(1):19-28. Review. French.

PMID:
10081033
40.

[Physiopathology of parathyroid hyperplasia].

Fournier A, Oprisiu R, Yverneau-Hardy P, Achard JM, Hottelart C, Westeel PF, Pruna A.

Presse Med. 1998 Sep 12;27(26):1355-61. Review. French. No abstract available.

PMID:
9779057
41.

[Role of phosphate, vitamin D and acidosis in the secretion and synthesis of parathyroid hormone at the cellular level].

Fournier A, Hottelart C, Yverneau-Hardy P, Ghazali A, Oprisiu R, Said S, Westeel PF, Achard JM, Pruna A.

Presse Med. 1998 Sep 12;27(26):1349-54. Review. French. No abstract available.

PMID:
9779056
42.

[Role of calcium and magnesium in the secretion and the synthesis of parathyroid hormone at the cellular level].

Fournier A, Yverneau-Hardy P, Ghazali A, Oprisiu R, Hottelart C, Said S, Westeel PF, Achard JM, Pruna A.

Presse Med. 1998 Sep 12;27(26):1338-48. Review. French. No abstract available.

PMID:
9779055
43.

[Pulmonary cavitated opacity in immunocompromised patient].

Lamour C, Mayeux I, Westeel A, Westeel PF, Jounieaux V.

Rev Pneumol Clin. 1998 Feb;54(1):38-41. French.

PMID:
9769985
44.

[Long-term stability of bone mineral density in patients with renal transplant treated with cyclosporine and low doses of corticoids. Protective role of cyclosporine?].

Ezaitouni F, Westeel PF, Fardellone P, Mazouz H, Brazier M, el Esper I, Sebert JL, Petit J, Westeel A, Pruna A, Fournier A.

Presse Med. 1998 Apr 18;27(15):705-12. Review. French.

PMID:
9767908
45.

Renal osteodystrophy in dialysis patients: diagnosis and treatment.

Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.

Artif Organs. 1998 Jul;22(7):530-57. Review.

PMID:
9684690
46.

[Thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome in adults. Apropos of 27 cases].

Hamdini N, Makdassi R, Tribout B, De Cagny B, Westeel PF, Fournier A.

Ann Med Interne (Paris). 1997;148(5):346-55. Review. French.

PMID:
9538408
47.

The clinical significance of adynamic bone disease in uremia.

Fournier A, Said S, Ghazali A, Sechet A, Ezaitouni F, Marie A, Westeel PF, Morinière P, Boudailliez B.

Adv Nephrol Necker Hosp. 1997;27:131-66. Review. No abstract available.

PMID:
9408446
48.

1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.

Fournier A, Morinière PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.

Nephron. 1995;71(3):254-83. Review.

PMID:
8569975
49.

[Vitamin D treatment and renal osteodystrophy: indications and modalities].

Fournier A, Morinière P, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.

Nephrologie. 1995;16(2):165-90. Review. French.

PMID:
7753302
50.

Hypertension and progression of renal insufficiency.

Fournier A, el Esper N, Makdassi R, Hué P, Westeel PF, Achard JM, Lalau JD.

Nephrol Dial Transplant. 1994;9 Suppl 3:28-34. Review.

PMID:
8072721

Supplemental Content

Loading ...
Support Center